Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ChimeriVax Dengue Vaccine in Previously Immunized Adults
NCT00730288Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Aug 2007
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, sponsored by Sanofi. Started Aug 2006; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00730288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00730288.